Literature DB >> 3592139

Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients.

L C Laursen, P Faurschou, H Pals, U G Svendsen, B Weeke.   

Abstract

In a double-blind group comparative study, 36 adult, birch pollen-allergic outpatients with seasonal rhinoconjunctivitis, were treated with either oral prednisolone 7.5 mg daily for 3 weeks or an injection with 2 ml suspension of betamethasone dipropionate and betamethasone disodium phosphate (Diprospan) immediately prior to the birch pollen season. Both treatments were able to prevent an increase in symptoms from the nose and the eyes during the 3-week birch pollen season. There was no significant difference in symptom score or nasal peak flow between the two treatments. However, there was a significant suppression of adrenal gland function after oral prednisolone treatment in contrast to Diprospan treatment. Unless there are contraindications for treatment with depot steroid injections (children, pregnant women, patients suffering from peptic ulcer, tuberculosis, eye disease, herpes, hypertension or diabetes) it seems to be a reasonable alternative to oral prednisolone in hay fever patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592139     DOI: 10.1111/j.1398-9995.1987.tb02194.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

2.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

Review 3.  Intramuscular corticosteroid injections in seasonal allergic rhinitis: A systematic review.

Authors:  Ahmed B Bayoumy; Felicia van Schie; Inge Stegeman; Esther B Blijleven; Erwin L van der Veen; Jacob A de Ru
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-09-04

4.  Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology.

Authors:  Baharudin Abdullah; Amir Hamzah Abdul Latiff; Anura Michelle Manuel; Faizah Mohamed Jamli; Harvinder Singh Dalip Singh; Intan Hakimah Ismail; Jeevanan Jahendran; Jeyasakthy Saniasiaya; Kent Chee Keen Woo; Phaik Choo Khoo; Kuljit Singh; Nurashikin Mohammad; Sakinah Mohamad; Salina Husain; Ralph Mösges
Journal:  J Asthma Allergy       Date:  2022-08-02

5.  Gluteal subcutaneous atrophy after depot steroid injection for allergic rhinitis.

Authors:  Rohan Ameratunga
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

Review 6.  Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper.

Authors:  Valerie Hox; Evelijn Lourijsen; Arnout Jordens; Kristian Aasbjerg; Ioana Agache; Isam Alobid; Claus Bachert; Koen Boussery; Paloma Campo; Wytske Fokkens; Peter Hellings; Claire Hopkins; Ludger Klimek; Mika Mäkelä; Ralph Mösges; Joaquim Mullol; Laura Pujols; Carmen Rondon; Michael Rudenko; Sanna Toppila-Salmi; Glenis Scadding; Sophie Scheire; Peter-Valentin Tomazic; Thibaut Van Zele; Martin Wagemann; Job F M van Boven; Philippe Gevaert
Journal:  Clin Transl Allergy       Date:  2020-01-03       Impact factor: 5.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.